2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients
Status:
Completed
Trial end date:
2017-07-10
Target enrollment:
Participant gender:
Summary
The aim of the present study is to evaluate the superiority of the fixed triple therapy with
BDP/FF/GB at a daily dose of 400/24/50 mcg respectively with that of Ultibro® Breezhaler®
(DPI), fixed combination of indacaterol 85 mcg and of glycopyrronium 43 mcg in COPD patients.